#77 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians may be unaware of cannabis use in 80% of older patients who use it, creating a critical gap in medication interaction screening and adverse event identification since cannabis can potentiate sedatives, anticoagulants, and other commonly prescribed geriatric medications. This disclosure gap prevents clinicians from providing evidence-based counseling on cannabis safety, dosing, and alternatives for conditions like chronic pain and insomnia that older adults frequently self-treat with cannabis. Establishing trust-based communication about cannabis use and developing standardized screening protocols is essential for delivering comprehensive geriatric care and reducing preventable drug interactions and falls.
A recent study demonstrates that fewer than 20% of older adults who use cannabis disclose this use to their physicians, representing a significant gap in clinical communication that may compromise patient safety and care quality. This disclosure failure occurs despite the lack of established clinical guidance on cannabis use in older populations, leaving physicians unable to assess potential drug interactions, contraindications, or age-related risks associated with cannabis products. The study underscores a critical challenge in geriatric medicine, as older adults may be using cannabis for pain, anxiety, or sleep without their healthcare providers’ knowledge, potentially compounding risks from polypharmacy or underlying medical conditions common in this age group. The communication barrier may stem from patient concerns about legal consequences, physician judgment, or lack of awareness about the relevance of cannabis to their medical care. Clinicians should proactively establish a non-judgmental clinical environment and specifically ask older patients about cannabis use during medication reviews and comprehensive assessments, as this disclosure is essential for identifying drug interactions and optimizing treatment safety in an aging population increasingly turning to cannabis products.
“The fact that 80 percent of older cannabis users aren’t disclosing to their physicians represents a genuine patient safety gap, because we can’t effectively manage drug interactions, monitor for adverse effects, or adjust other medications intelligently when we don’t have complete information about what patients are actually taking.”
💊 The underreporting of cannabis use among older adults represents a significant clinical blind spot that could compromise medication safety and clinical decision-making. This communication gap is particularly concerning given that older patients often take multiple medications with potential cannabinoid interactions, have age-related changes in drug metabolism, and may experience cannabis-related adverse effects (such as falls or cognitive changes) that clinicians might misattribute to other causes. The reasons for non-disclosure are likely multifactorial, including lingering stigma, uncertainty about legal status, assumptions that doctors disapprove, or simply not perceiving cannabis as a “medication” worth reporting. Clinicians should proactively and non-judgmentally ask about cannabis use as part of comprehensive medication reconciliation in older populations, similar to alcohol and supplement screening, while being prepared to discuss potential risks including drug interactions, fall risk, and cardiovascular effects in this vulnerable age group. Creating a normalized, judgment-free environment
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
